IQVIA Holdings, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick B Donnelly from Citi maintained a Hold rating on the stock and has a $200.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick B Donnelly has given his Hold rating due to a combination of factors including IQVIA Holdings’ recent financial performance and market expectations. The company’s third-quarter revenue of $4.10 billion was in line with the consensus estimate of $4.08 billion, while adjusted earnings per share slightly exceeded expectations. However, the TAS revenue was slightly below consensus, and the adjusted EBITDA margin was roughly in line with expectations, indicating stable but not exceptional performance.
Furthermore, IQVIA’s narrowed full-year guidance reflects a cautious outlook, maintaining revenue and EBITDA midpoints despite challenges such as trial delays and cancellations. The company’s backlog growth and booking dynamics suggest a steady pipeline, yet the expected share price return of -8.0% indicates limited upside potential in the near term. These elements collectively support the Hold rating, as they suggest a balanced risk-reward scenario for investors.
In another report released on October 13, Robert W. Baird also maintained a Hold rating on the stock with a $224.00 price target.